Senti Biosciences (SNTI) Appoints Fran Schulz to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow rise as AI boost counters US-Iran tensions
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
Senti Bio Appoints Fran Schulz to Board of Directors
December 2, 2024 7:00 AM ESTSOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (Senti Bio or the Company), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Fran Schulz, a highly experienced biotechnology and financial executive, to the Senti Bio Board of Directors (Board).
We are excited to welcome Fran to the Senti Bio Board of Directors, said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. Fran's deep expertise in the life sciences industryspanning finance, strategic planning,... More
